Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Afimetoran - Bristol-Myers Squibb

Next Previous
Drug Profile

Afimetoran - Bristol-Myers Squibb

Alternative Names: BMS-986256; TLR 7/8 Antagonist - Bristol-Myers Squibb; TLR 7/8 inhibitor - Bristol-Myers Squibb; Toll-like receptor 7/8 antagonist - Bristol-Myers Squibb

Latest Information Update: 21 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class 2 ring heterocyclic compounds; Acetamides; Antineoplastics; Indoles; Monoclonal antibodies; Piperidines; Pyridines; Skin disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus
  • Phase I Autoimmune disorders; Unspecified
  • Discontinued Cutaneous lupus erythematosus

Most Recent Events

  • 12 Jun 2024 Pharmacodynamics, efficacy and adverse events data from a phase Ib trial in Systemic lupus erythematosus presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
  • 19 Dec 2023 Discontinued - Phase-I for Cutaneous lupus erythematosus in Germany (PO) (Bristol-Myers Squibb Pipeline, December 2023)
  • 10 Nov 2023 Efficacy and adverse events data from a phase Ib trial in cutaneous lupus erythematosus presented at the ACR Convergence 2023 (ACR/ARP-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top